Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy
详细信息 查看全文
- 作者：Joana Felixa ; b ; Bruno Cassinatc ; d ; Raphael Porchere ; f ; g ; Marie-Hé ; lè ; ne Schlageterc ; Eve Maubech ; Cé ; cile Pagesi ; Barouyr Baroudjiani ; Laurence Homyrdaj ; Wahid Boukouacia ; b ; Ryad Tamouzaa ; b ; Martine Bagotb ; i ; k ; Anne Caignarda ; Antoine Touberta ; b ; Cé ; leste Lebbé ; b ; i ; k ; Hé ; lè ; ne Moins-Teisserenca ; b ; helene.moins@univ-paris-diderot.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Immunotherapy ; Melanoma ; CTLA-4 ; S100 ; LDH ; sMICA
- 刊名：International Immunopharmacology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：40
- 期：Complete
- 页码：466-473
- 全文大小：515 K
文摘
- •
Immuno-monitoring of advanced melanoma patients treated with ipilimumab
- •
Assessing serum biomarkers of response and survival in melanoma patients
- •
Low levels of S100B and LDH correlate to a better response and survival.
- •
High baseline sMICA serum levels confer a protective status towards irAEs.